EndoQuest Robotics Announces Installation of the First Endoluminal Surgical System to Advance the Clinical and Procedural Development of the ELS System at Brigham and Women’s Hospital in Boston, Massachusetts

ENDOQUEST Robotics today announced that the company’s proprietary Endoluminal Surgical (ELS) System will be installed at Brigham and Women’s Hospital (BWH) in Boston, MA.  The ELS System is the world’s first endoluminal robotic surgical system that makes it possible for therapeutic endoscopists and surgeons to perform scar-free upper and lower gastrointestinal surgery less-invasively through a trans-oral or trans-anal approach.

“Successful endoluminal surgery requires innovation in technology and procedural techniques,” said Christopher C. Thompson, MD, Professor of Medicine and Director of Endoscopy, Brigham and Women’s Hospital.  “The EndoQuest System is the world’s first fully robotic platform specifically designed for gastrointestinal tract surgery and can enable endoscopists to perform many procedures that are very challenging or not possible today.”

EndoQuest’s Endoluminal Surgical System represents an innovative advance in minimally invasive surgery that combines the flexibility of conventional endoscopy with the advantages of traditional surgical techniques to improve control and outcomes.  With this technology, therapeutic endoscopists and surgeons can perform a range of surgeries by accessing target disease sites directly through the body’s existing lumens. The ELS System design features a proprietary endoscope that works as a flexible and steerable overtube supporting the use of two surgical instruments and a videoscope.  The minimally invasive procedures can be performed using only internal incisions that do not result in visible scarring.  The enhanced capabilities of the robotic ELS System bring endoscopists and surgeons new levels of precision and control they need to use surgical techniques that were not previously possible.

“We are very pleased to partner with Brigham and Women’s Hospital, a global leader in innovation in endoluminal surgery, and look forward to working with them to advance the clinical and procedural development of the ELS System,” said Kurt Azarbarzin, Chief Executive Officer of EndoQuest Robotics.  “We also hope to expand this relationship to include BWH as a center for our planned IDE clinical study in late 2023 and as our first Center of Excellence and training facility in the U.S.”

SourceEndoQuest

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”